Adults with Down syndrome are at a significantly higher risk of developing Alzheimer’s disease due to their unique genetic makeup. As exciting new clinical trials open for Alzheimer’s therapies specifically welcoming individuals with Down syndrome, families have more opportunities than ever to participate in groundbreaking research.
To help families better understand these new opportunities, LuMind IDSC has developed a free, easy-to-understand guide:
“Understanding Key Differences Among the Current & Emerging Alzheimer’s Clinical Trials in Down Syndrome.”
This guide explains, in non-scientific language:
- Why individuals with Down syndrome are at higher risk for Alzheimer’s
- The different types of therapies being studied (including vaccines, antibody treatments, and genetic therapies)
- How each therapy works
- What families should know about participating in clinical research
The guide also offers a side-by-side comparison of three major studies currently enrolling or preparing to enroll individuals with Down syndrome:
- HERO Study – investigating antisense oligonucleotides to reduce harmful protein production
- ABATE Study – testing a vaccine to help clear harmful amyloid plaques
- ALADDIN Study – preparing to study an antibody therapy already approved for typical early Alzheimer’s
This resource is free and available both as a downloadable/printable PDF and a browseable web page:
If you are interested in more information, or if your family would like to learn through a webinar presentation, you can reach out to the team at LuMind IDSC directly.
Why This Matters
Clinical research participation is critical for developing treatments tailored to the needs of individuals with Down syndrome.
Every family deserves clear, accessible information to make the best decisions for their loved one’s future.
We are grateful to LuMind IDSC for creating this important guide — and we encourage all of our families to explore it, share it, and learn more about how research participation can support better outcomes for our community.
Together, we move closer to a future where individuals with Down syndrome live longer, healthier, and even more empowered lives.